Cargando…

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

[Image: see text] SARS-CoV-2 main protease (M(pro)) is a cysteine protease that mediates the cleavage of viral polyproteins and is a validated antiviral drug target. M(pro) is highly conserved among all seven human coronaviruses, with certain M(pro) inhibitors having broad-spectrum antiviral activit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Zilei, Sacco, Michael, Hu, Yanmei, Ma, Chunlong, Meng, Xiangzhi, Zhang, Fushun, Szeto, Tommy, Xiang, Yan, Chen, Yu, Wang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204911/ https://www.ncbi.nlm.nih.gov/pubmed/34414360 http://dx.doi.org/10.1021/acsptsci.1c00099

Ejemplares similares

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
por: Hu, Yanmei, et al.
Publicado: (2020)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
por: Wang, Yining, et al.
Publicado: (2022)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay
por: Xia, Zilei, et al.
Publicado: (2021)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
por: Ma, Chunlong, et al.
Publicado: (2021)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
por: Kjellin, Midori, et al.
Publicado: (2018)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis
por: Sharun, Khan, et al.
Publicado: (2020)

Boceprevir
Publicado: (2012)

Interaction of GC376, a SARS-COV-2 M(PRO) inhibitor, with model lipid membranes
por: Klacsová, Mária, et al.
Publicado: (2022)

A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection
por: Chen, Yongkang, et al.
Publicado: (2023)

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
por: Coilly, Audrey, et al.
Publicado: (2015)

Rational Design of a Peptidomimetic Inhibitor of Gelsolin Amyloid Aggregation
por: Bollati, Michela, et al.
Publicado: (2022)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376
por: Ye, Gang, et al.
Publicado: (2020)

Protease inhibitors and their peptidomimetic derivatives as potential drugs
por: Fear, Georgie, et al.
Publicado: (2007)

The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract
por: Shi, Yuejun, et al.
Publicado: (2021)

Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis
por: Lv, Jinbao, et al.
Publicado: (2022)

Boceprevir-induced Herpes Zoster
por: Babalı, Ayşegul, et al.
Publicado: (2018)

Crystallization of Feline Coronavirus M(pro) With GC376 Reveals Mechanism of Inhibition
por: Lu, Jimmy, et al.
Publicado: (2022)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection
por: Mohammad, Al Wahadneh, et al.
Publicado: (2023)

IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders
por: Calisti, Giorgio, et al.
Publicado: (2015)

Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376
por: Luan, Xiao-dong, et al.
Publicado: (2022)

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
por: Alugubelli, Yugendar R., et al.
Publicado: (2022)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0cs57v3vunp8o5tn00h1m8jhpb